Calypte faces delisting by the American Stock Exchange

By Lisa Kerner

Erie, Pa., Feb. 3 - Calypte Biomedical Corp. said it was notified on Thursday by the American Stock Exchange that the company no longer complies with the exchange's continued listing standards.

Specifically, the company is not in compliance with rules regarding shareholders' equity and net losses, according to a company news release.

As a result, the exchange's staff has determined to begin delisting proceedings for Calypte's common stock.

The company said it has until Feb. 10 to request an appeal of the Exchange's determination. Calypte said it plans to request a hearing be held, within the 45 days of the request as required, before a committee of the exchange.

Calypte, based in Oswego, Ore., develops diagnostic testing products for the detection of sexually transmitted diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.